A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 19 Sep 2019 Planned primary completion date changed from 30 Nov 2019 to 1 Feb 2020.
- 19 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2019 Planned End Date changed from 31 Jan 2023 to 31 Aug 2024.